Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 5/2015

01-05-2015 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Cardiovascular, Renal and Overall Health Outcomes After Bariatric Surgery

Authors: Ji C. Tham, Carel W. le Roux, Neil G. Docherty

Published in: Current Cardiology Reports | Issue 5/2015

Login to get access

Abstract

Obesity is associated with significant increases in morbidity and mortality secondary, in part, to the increased burden of cardiovascular and renal diseases. Currently, bariatric surgery represents an important component of intensive approaches to the treatment of chronic and complex obesity. The efficacy of bariatric surgery extends beyond its ability to support significant and sustainable reductions in bodyweight to improvements in metabolic and cardiovascular health which are proposed to occur, in part, via weight loss-independent physiological changes. This report summarises the concept of cardiovascular and renal diseases as important constituent aspects of obese morbidity that contribute to overall impairments in health and lifespan. It furthermore describes the key features of bariatric surgical interventions, the evidence base for their beneficial effect on cardiovascular and renal diseases, and lastly provides some perspectives on the mechanisms involved.
Literature
1.••
Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton Obesity Staging System to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183(14):E1059–66. The authors described a method of classifying obese patients according to co-morbidities instead of BMI which better stratifies the potential benefit achievable from bariatric surgery.CrossRefPubMedCentralPubMed
2.
Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–8.CrossRefPubMedCentralPubMed
3.
Kushner RF, Ryan DH. Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews. JAMA. 2014;312(9):943–52.CrossRefPubMed
4.
Christiansen T, Bruun JM, Madsen EL, Richelsen B. Weight loss maintenance in severely obese adults after an intensive lifestyle intervention: 2- to 4-year follow-up. Obesity (Silver Spring). 2007;15(2):413–20.CrossRef
5.•
Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54. Part of the Look AHEAD research group that scrutinised the possible management of obesity with lifestyle intervention but found that cardiovascular outcomes were no different when compared to control subjects.CrossRefPubMed
6.
Group LAR. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(10):801–9.CrossRef
7.
Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467–84. discussion 84–5.PubMedCentralPubMed
8.•
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13. The authors describe a landmark study that compared bariatric surgery with medical therapy against medical therapy alone in the management of type 2 diabetes mellitus instead of the traditional surgery versus medical treatment. The message portrayed from the study proposes surgery as an adjunct to medical therapy in the treatment of obese patients.CrossRefPubMed
9.•
Carlsson LM, Romeo S, Jacobson P, Burza MA, Maglio C, Sjöholm K, et al. The incidence of albuminuria after bariatric surgery and usual care in Swedish obese subjects (SOS): a prospective controlled intervention trial. Int J Obes (Lond). 2014. The study shows the reversal of kidney damage as a result of bariatric surgery in the long-term.
10.
Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367(8):695–704.CrossRefPubMed
11.
Delling L, Karason K, Olbers T, Sjöström D, Wahlstrand B, Carlsson B, et al. Feasibility of bariatric surgery as a strategy for secondary prevention in cardiovascular disease: a report from the Swedish obese subjects trial. J Obes. 2010.
12.
Hallersund P, Sjöström L, Olbers T, Lönroth H, Jacobson P, Wallenius V, et al. Gastric bypass surgery is followed by lowered blood pressure and increased diuresis—long term results from the Swedish Obese Subjects (SOS) study. PLoS One. 2012;7(11):e49696.CrossRefPubMedCentralPubMed
13.
Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.CrossRefPubMed
14.•
Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65. The authors revealed that cardiovascular adverse events are more likely in patients with a high baseline insulin level instead of a high BMI; suggesting that management should focus on patients with poorly controlled diabetes and maintenance of good glycaemic control is vital.CrossRefPubMed
15.
Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34.CrossRefPubMed
16.•
Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. This study is landmark study with very long-term follow-up that showed a high rate of type 2 diabetes mellitus remission and reduction in macrovascular and microvascular complications.CrossRefPubMed
17.
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012.
18.
Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361(5):445–54.CrossRefPubMed
19.••
Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310(22):2416–25. This study showed that weight loss outcomes fall into different distinct patterns, suggesting possible different aetiology of obesity and response to bariatric surgery.PubMedCentralPubMed
20.
O’Brien PE, Dixon JB, Brown W, Schachter LM, Chapman L, Burn AJ, et al. The laparoscopic adjustable gastric band (Lap-Band): a prospective study of medium-term effects on weight, health and quality of life. Obes Surg. 2002;12(5):652–60.CrossRefPubMed
21.
Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.CrossRefPubMed
22.
Puzziferri N, Roshek TB, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA. 2014;312(9):934–42.CrossRefPubMed
23.
Sultan S, Gupta D, Parikh M, Youn H, Kurian M, Fielding G, et al. Five-year outcomes of patients with type 2 diabetes who underwent laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2010;6(4):373–6.CrossRefPubMed
24.
Committee ACI. Updated position statement on sleeve gastrectomy as a bariatric procedure. Surg Obes Relat Dis. 2012;8(3):e21–6.CrossRef
25.
Rosenthal RJ, Diaz AA, Arvidsson D, Baker RS, Basso N, Bellanger D, et al. International sleeve gastrectomy expert panel consensus statement: best practice guidelines based on experience of >12,000 cases. Surg Obes Relat Dis. 2012;8(1):8–19.CrossRefPubMed
26.
Trastulli S, Desiderio J, Guarino S, Cirocchi R, Scalercio V, Noya G, et al. Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surg Obes Relat Dis. 2013;9(5):816–29.CrossRefPubMed
27.
Gill RS, Birch DW, Shi X, Sharma AM, Karmali S. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6(6):707–13.CrossRefPubMed
28.
Higa KD, Boone KB, Ho T, Davies OG. Laparoscopic Roux-en-Y gastric bypass for morbid obesity: technique and preliminary results of our first 400 patients. Arch Surg. 2000;135(9):1029–33. discussion 33–4.CrossRefPubMed
29.
Dillemans B, Sakran N, Van Cauwenberge S, Sablon T, Defoort B, Van Dessel E, et al. Standardization of the fully stapled laparoscopic Roux-en-Y gastric bypass for obesity reduces early immediate postoperative morbidity and mortality: a single center study on 2606 patients. Obes Surg. 2009;19(10):1355–64.CrossRefPubMedCentralPubMed
30.
Jacobsen HJ, Bergland A, Raeder J, Gislason HG. High-volume bariatric surgery in a single center: safety, quality, cost-efficacy and teaching aspects in 2,000 consecutive cases. Obes Surg. 2012;22(1):158–66.CrossRefPubMed
31.
Hutter MM, Schirmer BD, Jones DB, Ko CY, Cohen ME, Merkow RP, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg. 2011;254(3):410–20. discussion 20–2.CrossRefPubMedCentralPubMed
32.
Birkmeyer NJ, Dimick JB, Share D, Hawasli A, English WJ, Genaw J, et al. Hospital complication rates with bariatric surgery in Michigan. JAMA. 2010;304(4):435–42.CrossRefPubMed
33.
DeMaria EJ, Murr M, Byrne TK, Blackstone R, Grant JP, Budak A, et al. Validation of the obesity surgery mortality risk score in a multicenter study proves it stratifies mortality risk in patients undergoing gastric bypass for morbid obesity. Ann Surg. 2007;246(4):578–82. discussion 83–4.CrossRefPubMed
34.
Poirier P, Alpert MA, Fleisher LA, Thompson PD, Sugerman HJ, Burke LE, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation. 2009;120(1):86–95.CrossRefPubMed
35.
Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123(15):1683–701.CrossRefPubMed
36.
Turgeon NA, Perez S, Mondestin M, Davis SS, Lin E, Tata S, et al. The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol. 2012;23(5):885–94.CrossRefPubMed
37.
Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care. 2010;33(8):1783–8.CrossRefPubMedCentralPubMed
38.
Oster G, Thompson D, Edelsberg J, Bird AP, Colditz GA. Lifetime health and economic benefits of weight loss among obese persons. Am J Public Health. 1999;89(10):1536–42.CrossRefPubMedCentralPubMed
39.
Pi-Sunyer FX. Short-term medical benefits and adverse effects of weight loss. Ann Intern Med. 1993;119(7 Pt 2):722–6.CrossRefPubMed
40.
Liu RC, Sabnis AA, Forsyth C, Chand B. The effects of acute preoperative weight loss on laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2005;15(10):1396–402.CrossRefPubMed
41.
Zerrweck C, Maunoury V, Caiazzo R, Branche J, Dezfoulian G, Bulois P, et al. Preoperative weight loss with intragastric balloon decreases the risk of significant adverse outcomes of laparoscopic gastric bypass in super-super obese patients. Obes Surg. 2012.
42.
Adams TD, Pendleton RC, Strong MB, Kolotkin RL, Walker JM, Litwin SE, et al. Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese. Obesity (Silver Spring). 2010;18(1):121–30.CrossRef
43.
Karlsson J, Taft C, Rydén A, Sjöström L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond). 2007;31(8):1248–61.CrossRef
44.
Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–61.CrossRefPubMed
45.
Serés L, Lopez-Ayerbe J, Coll R, Rodriguez O, Vila J, Formiguera X, et al. Increased exercise capacity after surgically induced weight loss in morbid obesity. Obesity (Silver Spring). 2006;14(2):273–9.CrossRef
46.
Valezi AC, Machado VH. Morphofunctional evaluation of the heart of obese patients before and after bariatric surgery. Obes Surg. 2011;21(11):1693–7.CrossRefPubMed
47.
Haller H. Epidermiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med. 1977;32(8):124–8.PubMed
48.
P B. The lean patient with type 2 diabetes: characteristics and therapy challenge. Int J Clin Pract Suppl. 2007;1533–9.
49.•
Fenske WK, Dubb S, Bueter M, Seyfried F, Patel K, Tam FW, et al. Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2012. The authors described the effects of bariatric surgery on the metabolic syndrome whereby the hallmark mild chronic inflammatory response in obesity is diminished in the post-operative setting.
50.
Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012.
51.
Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial. JAMA. 2013;309(21):2240–9.CrossRefPubMedCentralPubMed
52.
de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417–26.CrossRefPubMed
53.
Lieske JC, Collazo-Clavell ML, Sarr MG, Rule AD, Bergstralh EJ, Kumar R. Gastric bypass surgery and measured and estimated GFR in women. Am J Kidney Dis. 2014;64(4):663–5.CrossRefPubMedCentralPubMed
54.
Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740–8.CrossRefPubMedCentralPubMed
55.
Pournaras DJ, Osborne A, Hawkins SC, Vincent RP, Mahon D, Ewings P, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252(6):966–71.CrossRefPubMed
56.•
Vallon V, Docherty NG. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. Exp Physiol. 2014;99(9):1140–5. The authors discuss the effects of glucagon-like peptide 1 on renal function and suggest the possible mechanism of improvements in renal function as a result on glucagon-like peptide receptor stimulation.CrossRefPubMed
57.
Docherty NG, le Roux CW. Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease. Exp Physiol. 2014;99(9):1146–53.CrossRefPubMed
58.
Miras AD, Chuah LL, Lascaratos G, Faruq S, Mohite AA, Shah PR, et al. Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care. 2012;35(12):e81.CrossRefPubMedCentralPubMed
Metadata
Title
Cardiovascular, Renal and Overall Health Outcomes After Bariatric Surgery
Authors
Ji C. Tham
Carel W. le Roux
Neil G. Docherty
Publication date
01-05-2015
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 5/2015
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-015-0588-6

Other articles of this Issue 5/2015

Current Cardiology Reports 5/2015 Go to the issue

Cardiac PET, CT, and MRI (SE Petersen, Section Editor)

Interventional CMR: Clinical Applications and Future Directions

Interventional Cardiology (S Rao, Section Editor)

Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk

Ischemic Heart Disease (D Mukherjee, Section Editor)

Racial Disparities in Outcomes After Cardiac Surgery: the Role of Hospital Quality

Cardiac PET, CT, and MRI (SE Petersen, Section Editor)

Cardiac PET for Translational Imaging

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

New Insights into the Role of Nutrition in CVD Prevention

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits